インフルエンザ診断薬市場：検査タイプ別、エンドユーザー別-2025-2030年の世界予測

インフルエンザ診断薬市場は、2023年に12億米ドルと評価され、2024年には13億2,000万米ドルに達すると予測され、CAGR 9.86%で成長し、2030年には23億2,000万米ドルに達すると予測されています。

インフルエンザ診断薬市場には、インフルエンザウイルス感染を特定するためのツールやプロセスが含まれます。その必要性は、毎年大きな罹患率と死亡率を引き起こすインフルエンザウイルスの世界的流行に起因しています。迅速で正確な診断は、患者管理、疫学的サーベイランス、アウトブレイクの予防に不可欠です。これらの診断薬の用途は、病院、診療所、診断研究所、研究機関に及び、臨床判断の指針、公衆衛生対応の管理、ワクチン開発などに不可欠です。さらに、インフルエンザ株の中には人畜共通感染症に罹患するものもあるため、最終用途にはヒトのヘルスケアと獣医学的用途の両方が含まれます。

インフルエンザ診断薬市場の主な成長要因としては、技術の進歩、ポイントオブケア検査需要の増加、近年のパンデミックによる感染症への注目の高まりなどが挙げられます。人口の高齢化と慢性呼吸器疾患の罹患率の上昇が需要をさらに促進し、市場は力強い成長を遂げます。市場開拓の機会としては、複数の病原体を同時に検査できるマルチプレックス診断プラットフォームの開発があり、効率と患者の予後を向上させることができます。企業は、ヘルスケアのインフラ整備によって診断薬へのアクセスが拡大している新興市場への進出を生かすことができます。

しかし、高度な診断薬の価格が高いこと、地域によっては保険償還が限られていること、複雑な診断機器を操作するには熟練した専門家が必要であることなどが、市場成長の課題となる可能性があります。さらに、インフルエンザウイルスの急速な変異は、効果的な診断法の開発を複雑にしています。イノベーションの機会は、CRISPR技術や紙ベースのバイオセンサーを使用したものなど、より迅速でコスト効率が高く、使いやすい診断ソリューションの開発にあります。さらに、人工知能を統合して診断精度を向上させ、インフルエンザの発生を予測することは、研究と事業成長のための有望な領域を提供します。市場は急速な技術進化と競争の激しさを特徴としており、競争力を維持するためには継続的な技術革新と戦略的提携が必要です。

市場力学：急速に進化するインフルエンザ診断薬市場の主要市場インサイトを公開

インフルエンザ診断薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • インフルエンザの流行とインフルエンザスクリーニング検査の増加
  • インフルエンザ診断薬に関する研究資金の増加
  • 特定の診断検査を用いた早期発見・早期診断に対する意識の高まり
• 市場抑制要因
  • 新しい診断検査の承認に関する厳しい規制の枠組み
• 市場機会
  • CLIA免除のPOC分子インフルエンザ検査などの高度診断検査の開発
  • 強力な販売網の利用可能性
• 市場の課題
  • ヘルスケアコストの上昇

ポーターの5つの力：インフルエンザ診断薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：インフルエンザ診断薬市場における外部からの影響の把握

外部マクロ環境要因は、インフルエンザ診断薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析インフルエンザ診断薬市場における競合情勢の把握

インフルエンザ診断薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスインフルエンザ診断薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、インフルエンザ診断薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨インフルエンザ診断薬市場における成功への道筋を描く

インフルエンザ診断薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • インフルエンザの流行とインフルエンザスクリーニング検査の増加
    • インフルエンザ診断薬の調査資金の増加
    • 特定の診断検査による早期発見と迅速な診断に対する意識の高まり
  • 抑制要因
    • 新しい診断検査の承認に関する厳格な規制枠組み
  • 機会
    • CLIA免除POC分子インフルエンザ検査などの高度な診断検査の開発
    • 強力な流通ネットワークの可用性
  • 課題
    • ヘルスケア費の高騰
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 インフルエンザ診断薬市場テストタイプ別

• 細胞培養
• インフルエンザ迅速診断検査
• 逆転写ポリメラーゼ連鎖反応

第7章 インフルエンザ診断薬市場：エンドユーザー別

• 病院
• 研究所
• ポイントオブケア検査

第8章 南北アメリカのインフルエンザ診断薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域のインフルエンザ診断薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカのインフルエンザ診断薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Aetna Inc.
• Becton, Dickinson and Company
• Cepheid
• Co-Diagnostics, Inc.
• DIASORIN MOLECULAR LLC
• F. Hoffmann-La Roche Ltd.
• Luminex Corporation
• Merck KGaA
• Quidel Corporation
• SA Scientific Ltd.
• Sansure Biotech Inc.
• Secure Diagnostics Pvt. Ltd.
• Sekisui Diagnostics, LLC
• Thermo Fisher Scientific Inc.

LIST OF FIGURES

• FIGURE 1. INFLUENZA DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 2. INFLUENZA DIAGNOSTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES INFLUENZA DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES INFLUENZA DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. INFLUENZA DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. INFLUENZA DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. INFLUENZA DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. INFLUENZA DIAGNOSTICS MARKET DYNAMICS
• TABLE 7. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CELL CULTURE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID INFLUENZA DIAGNOSTIC TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 18. ARGENTINA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 19. ARGENTINA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 20. BRAZIL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 21. BRAZIL INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 22. CANADA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 23. CANADA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 24. MEXICO INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 25. MEXICO INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 26. UNITED STATES INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 27. UNITED STATES INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 28. UNITED STATES INFLUENZA DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 29. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 30. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 31. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 32. AUSTRALIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 33. AUSTRALIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. CHINA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 35. CHINA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 36. INDIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 37. INDIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 38. INDONESIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 39. INDONESIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 40. JAPAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 41. JAPAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. MALAYSIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 43. MALAYSIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 44. PHILIPPINES INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 45. PHILIPPINES INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. SINGAPORE INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 47. SINGAPORE INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. SOUTH KOREA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 49. SOUTH KOREA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. TAIWAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 51. TAIWAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 52. THAILAND INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 53. THAILAND INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. VIETNAM INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 55. VIETNAM INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 57. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 59. DENMARK INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 60. DENMARK INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 61. EGYPT INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 62. EGYPT INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. FINLAND INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 64. FINLAND INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. FRANCE INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 66. FRANCE INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 67. GERMANY INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 68. GERMANY INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. ISRAEL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 70. ISRAEL INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. ITALY INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 72. ITALY INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. NETHERLANDS INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 74. NETHERLANDS INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. NIGERIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 76. NIGERIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. NORWAY INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 78. NORWAY INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 79. POLAND INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 80. POLAND INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. QATAR INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 82. QATAR INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 83. RUSSIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 84. RUSSIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. SAUDI ARABIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 86. SAUDI ARABIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. SPAIN INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 90. SPAIN INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. SWEDEN INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 92. SWEDEN INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. SWITZERLAND INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 94. SWITZERLAND INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. TURKEY INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 96. TURKEY INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. UNITED ARAB EMIRATES INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 98. UNITED ARAB EMIRATES INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 99. UNITED KINGDOM INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 100. UNITED KINGDOM INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 101. INFLUENZA DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 102. INFLUENZA DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Influenza Diagnostics Market was valued at USD 1.20 billion in 2023, expected to reach USD 1.32 billion in 2024, and is projected to grow at a CAGR of 9.86%, to USD 2.32 billion by 2030.

The influenza diagnostics market involves tools and processes used to identify influenza virus infections. Its necessity stems from the global prevalence of the influenza virus, which causes significant morbidity and mortality annually. Rapid and accurate diagnostics are crucial for patient management, epidemiological surveillance, and the prevention of outbreaks. The application of these diagnostics spans hospitals, clinics, diagnostic laboratories, and research institutions, where they are essential for guiding clinical decisions, managing public health responses, and developing vaccines. Additionally, their end-use includes both human healthcare and veterinary applications, given the zoonotic nature of some influenza strains.

Key growth factors in the influenza diagnostics market include technological advancements, increased demand for point-of-care testing, and a heightened focus on infectious diseases due to recent pandemics. The aging population and the rising incidence of chronic respiratory diseases further drive demand, positioning the market for robust growth. Opportunities in the market include the development of multiplex diagnostic platforms that can simultaneously test for multiple pathogens, enhancing efficiency and patient outcomes. Companies can capitalize on expanding into emerging markets where healthcare infrastructure improvements are increasing access to diagnostics.

However, market growth may be challenged by the high cost of advanced diagnostics, limited reimbursement in certain regions, and the need for skilled professionals to operate complex diagnostic equipment. Additionally, the rapid mutation of influenza viruses can complicate the development of effective diagnostics. Innovation opportunities lie in the development of faster, more cost-effective, and user-friendly diagnostic solutions, such as those using CRISPR technology or paper-based biosensors. Moreover, integrating artificial intelligence to improve diagnostic accuracy and predict influenza outbreaks offers a promising area for research and business growth. The market is characterized by rapid technological evolution and competitive intensity, necessitating continuous innovation and strategic partnerships to maintain a competitive edge.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Influenza Diagnostics Market

The Influenza Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Prevalence of influenza and increasing number of influenza screening test
  • Growth in research funding for influenza diagnostics
  • Growing awareness for early detection faster diagnosis using specific diagnostic tests
• Market Restraints
  • Stringent regulatory framework for the approval of new diagnostic tests
• Market Opportunities
  • Development of advanced diagnosis test such as CLIA-waived POC molecular influenza tests
  • Availability of strong distribution network
• Market Challenges
  • Rising healthcare costs

Porter's Five Forces: A Strategic Tool for Navigating the Influenza Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Influenza Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Influenza Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Influenza Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Influenza Diagnostics Market

A detailed market share analysis in the Influenza Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Influenza Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Influenza Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Influenza Diagnostics Market

A strategic analysis of the Influenza Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Influenza Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Aetna Inc., Becton, Dickinson and Company, Cepheid, Co-Diagnostics, Inc., DIASORIN MOLECULAR LLC, F. Hoffmann-La Roche Ltd., Luminex Corporation, Merck KGaA, Quidel Corporation, SA Scientific Ltd., Sansure Biotech Inc., Secure Diagnostics Pvt. Ltd., Sekisui Diagnostics, LLC, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Influenza Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Test Type, market is studied across Cell Culture, Rapid Influenza Diagnostic Tests, and Reverse Transcription-Polymerase Chain Reaction.
• Based on End-User, market is studied across Hospitals, Laboratories, and Point-Of-Care Testing.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of influenza and increasing number of influenza screening test
    • 5.1.1.2. Growth in research funding for influenza diagnostics
    • 5.1.1.3. Growing awareness for early detection faster diagnosis using specific diagnostic tests
  • 5.1.2. Restraints
    • 5.1.2.1. Stringent regulatory framework for the approval of new diagnostic tests
  • 5.1.3. Opportunities
    • 5.1.3.1. Development of advanced diagnosis test such as CLIA-waived POC molecular influenza tests
    • 5.1.3.2. Availability of strong distribution network
  • 5.1.4. Challenges
    • 5.1.4.1. Rising healthcare costs
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Influenza Diagnostics Market, by Test Type

• 6.1. Introduction
• 6.2. Cell Culture
• 6.3. Rapid Influenza Diagnostic Tests
• 6.4. Reverse Transcription-Polymerase Chain Reaction

7. Influenza Diagnostics Market, by End-User

• 7.1. Introduction
• 7.2. Hospitals
• 7.3. Laboratories
• 7.4. Point-Of-Care Testing

8. Americas Influenza Diagnostics Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Influenza Diagnostics Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Influenza Diagnostics Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Aetna Inc.
• 3. Becton, Dickinson and Company
• 4. Cepheid
• 5. Co-Diagnostics, Inc.
• 6. DIASORIN MOLECULAR LLC
• 7. F. Hoffmann-La Roche Ltd.
• 8. Luminex Corporation
• 9. Merck KGaA
• 10. Quidel Corporation
• 11. SA Scientific Ltd.
• 12. Sansure Biotech Inc.
• 13. Secure Diagnostics Pvt. Ltd.
• 14. Sekisui Diagnostics, LLC
• 15. Thermo Fisher Scientific Inc.